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Summary: Percutaneous absorption, excretion kinetics, and 
metabolism of dithranol triacetate (2) have been investigated 
in Wistar rats. By the use of two differently labelled mole-
cules - 3H in the anthracene nucleus and 1 4 C in the acetoxy 
groups of 2, resp. - the fate of the different parts of the dith-
ranol triacetate molecule could be followed. After injection, 
large amounts of 2 are cleaved under the influence of en-
zymes into acetate and dithranol. These deacetylated meta-
bolites lose half their 3H label with formation of3H20. In 
urine, l,8-diacetoxy-9-anthrone, 1-acetoxy-8-hydroxy-9-
anthrone, l,8-dihydroxy-9,10-anthraquinone and its diace-
tate were found as metabolites. 
After dermal application, unchanged 2 is practically not ab-
sorbed at all. Arylesterases which, according to in vitro stud-
ies, are present in or on the skin, hydrolyse dithranol triace-
tate to give free dithranol. Up to 33% of the latter are ab-
sorbed from under an occlusive dressing. Dithranol triace-
tate, therefore, shows pro-drug characteristics for the treat-
ment ofpsoriasis. 
Zusammenfassung: Dermale Resorption und Metabolisie-
rung des Antipsoriatikums Dithranol- triacetat 
Die perkutane Resorption, die Ausscheidungskinetik und der 
Metabolismus von Dithranol-triacetat (2) wurden bei Wi-
star-Ratten untersucht. Durch die Verwendung zweier ver-
schieden markierter Verbindungen - 3H im Anthracen-Teil 
und 1 4 C in den Acetat-Resten - konnte das Schicksal der 
verschiedenen Molekülteile verfolgt werden. Nach Injektion 
wird 2 in großem Umfang durch enzymatische Einwirkung 
in Acetat und Dithranol gespalten. Die desacetylierten Meta-
boliten verlieren zur Hälfte die 3Ii-Markierung unter Bil-
dung von 3H20. Als Stoffwechselprodukte wurden nach iv. 
Injektion von 3H-2 im Urin l,8-Diacetoxy-9-anthron, 
1 - Acetoxy- 8- hydroxy- 9- anthron, Dithranol, 1,8-Dihydroxy-
9,10-anthrachinon und dessen Diacetat gefunden. Bei der 
dermalen Verabreichung wird unverändertes 2 praktisch 
nicht resorbiert. Die in der Haut in vitro nachweisbaren 
Arylesterasen hydrolysieren jedoch 2 zu Dithranol, das unter 
einem Okklusiv-Verband bis zu 33% resorbiert wird. Di-
thranol-triacetat erweist damit seine Prodrug-Eigenschaften 
für die Psoriasis-Behandlung. 
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1. Introduction 
Dithranol (l,8-dihydroxy-9-anthrone) (1) is a proven anti-
psoriatic usually to be applied topically. Since it irritates 
healthy skin and causes brown discolouration [1], its use is 
mostly restricted to in-hospital treatment. For these reasons 
the colourless and less aggressive 1,8,9-triacetoxy-
anthracene (dithranol triacetate) (2) has been used instead, 
although it acts more slowly and more weakly. In a previous 
0 Preliminary communication: Arch. Derm. Res. 273, 163 (1982). 
publication [1] we investigated the metabolism of dithranol 
triacetate in serum, the results indicating both hydrolytic 
and oxidative pathways. 
The present work is concerned with dermal absorption and 
metabolism of 3 H - and 1 4C-dithranol triacetate in rats, as 
well as with metabolic reactions in vitro by homogenates of 
fresh mouse and rat skin. 
2. Materials and equipment 
2.1. Chemicals (see formula diagram) 
1,8,9-Triacetoxyanthracene (dithranol triacetate, 2); 1,8-dihydroxy-
9-anthrone (dithranol, 1); l-hydroxy-8-acetoxy-9-anthrone (dithra-
nol monoacetate, 4); l,8-diacetoxy-9-anthrone (dithranol diacetate, 
3); l,8-dihydroxy-9,10-anthraquinone (dantron, 5); l-hydroxy-8-
acetoxy-9,10-anthraquinone (dantron monoacetate, 7); 1,8-diacet-
oxy-9,10-anthraquinone (dantron diacetate, 6); l,l',8,8'-tetra-
hydroxy-10,10'-bisanthrone (8); aryl sulfatase/glucuronidase (12 
U/ml from Helix pomatia (Merck No. 4114)). 
Radiolabelled compounds 
l,8,9-Tri-[l-i4C]acetoxyanthracene (14C-2) [3]; 12.5 mCi/mmol [3]; 
l,8,9-triacetoxy-[G-3H]anthracene (3H-2) [3]; 400 mCi/mmol [3]; 
sodium [l-14C]acetate; 50 mCi/mmol (New England Nuclear, Bos-
ton, USA). 
2.2. Thin-layer chromatography 
TLC-Plates: Silica Gel 60 F 2 5 4 20 x 20 cm (Merck No. 5715). 
2.3. Measurement of radioactivity 
Liquid scintillation spectrometer: Packard Tri-Carb, model 3380/ 
544. 
Results were calculated as dpm with an external standard-channel 
ratio method. Samples were counted 3 times for 5 min. 
Radioactivity measurements on T L C plates were performed on a 
Berthold T L C Scanner II model-LB 2721 or LB 2723. Samples were 
oxidized before liquid scintillation counting with a Packard Tri-
Carb 306 Sample Oxidizer. 
2.4. Scintillation solutions 
a) Dioxane-based scintillator: 7 g PPO; 0.3 g dimethyl-POPOP; 100 
g naphthalene in 1000 ml dioxane;46 ml per sample. 
b) Omniscintisol® (Merck No. 15386), 10 ml per sample. 
3. Methods 
3.1. In vitro stability of radiolabeled compounds 
[3H]-2 and [14C]-2 were tested for both radiochemical homogeneity 
and chemical stability in protic solvents. Neither compound lost any 
amount of radioactivity in the form of [14C]acetic acid or 3 H 2 0 . 
3.2. Experimental animals 
Mice: male, weighing approx. 20 g (used in the experiments de-
scribed in 3.8.); origin: E M D N M R I (SPF). 
Rats: male, weighing approx. 200 g (used in the experiments de-
scribed in 3.3-3.8); origin: E M D Wi-AF/Han (SPF). 
3.3. Administration 
3.3.1. i.v. and p.o. 
[3H]-2 and [14C]-2 were both used undiluted with inactive material. 
The labelled compounds were stored as standard solutions in ben-
zene. The required amount of standard solution was evaporated to 
dryness in a stream of nitrogen, and the residual material dissolved 
in PEG 200. 0.1 ml of this solution was injected into one of the cau-
dal veins of each animal. 
For oral application, 0.5 ml of PEG 200 solution were given by ga-
vage. 
3.3.2. Percutaneous application 
a) A n aliquot of the standard solution containing approx. 40 ßCi 
(1.1 mg) of [14C]-2 was evaporated in a stream of nitrogen. After 
addition of 50 mg of petroleum jelly (white petrolatum) [4] the mass 
was melted and subsequently stirred until cooled off. 
Homogeneity of the preparation was ascertained by exact radioactiv-
ity measurements on samples taken from four different locations in 
the mixing vessel. 
The concentration mentioned above corresponds to approx. 2.2% of 
2 in white petrolatum. 
[3H]-2-ointment was prepared in the same way. 
Approx. 30 mg of this ointment (determined accurately by re-
weighing the unused portion) were applied to a 2 x 2 cm area of the 
skin on the back while massaging gently for 1 min. 
To protect the ointment from being licked off by the animal, and to 
optimise absorption through the skin, the treated area was covered 
by a piece of polyethylene foil [5]. 
b) 20 ß\ of a DMSO-solution [6] containing 16 /zCi (0.4 mg) of 
[14.C]-2 were applied to a 2 x 2 cm area and covered by a piece of 
polyethylene foil as above. 
3.4. Animal experiments 
During the experiments the rats were kept in closed metabolism 
cages through which a constant stream of air was drawn by a suction 
pump. The animals had unlimited access to standard feed and 
water. 
Urine and feces were collected separately, expired 1 4 C 0 2 was ab-
sorbed in a trap containing 40% aqueous ethanolamine solution as 
14C-carbamate [7]. The traps were changed at 24-h intervals. At trie 
end of the experiment, after 72 h, the animals were sacrificed. 
Mice were sacrificed upon arrival from the breeding station. 
3.5. Sample preparation and radioactivity measurements 
Samples of urine and plasma (0.2 ml in each case) were measured 
directly after addition of scintillator. A sample of the ethanolamine 
solution was diluted with 5 ml methanol, and 10 ml of scintillator 
were added. Solid samples (feces and tissues) were homogenized in 3 
times their volume of water, subsequently, an aliquot (1 g) was dried 
and oxidized. Skin was carefully dissolved in 20% NaOH and deco-
lourized with a few drops of H 2 0 2 . Radioactivity in the polyethylene 
foil was measured after oxidation. 
3.6. Determination of 3 H 2 0 in urine and plasma 
3 ml urine or plasma were freeze-dried. Co-distilled volatile organic 
material was removed from the distillate by absorption on activated 
charcoal. Approx. 1.8 ml of the water were redistilled, aliquots of 
0.5 ml of the final distillate were measured. 
3.7. Separation of urinary metabolites 
After administration of [3H]-2, 3 ml of the 24-h urine were shaken 
with 30 ml methylene chloride. After 15 min, the phases were sepa-
rated by centrifugation (3000 rpm). 20 ml of the organic layer were 
evaporated, and the residue dried by azeotropic distillation with 3 
portions of 0.2 ml chloroform and applied to a silica gel thin-layer 
plate. After development with toluene-methanol-glacial acetic acid 
(85 : 10: 5, v/v) the plate was scanned with a radio-TLC-scanner. 
Identification of radioactive zones was done by comparison with 
zones of the corresponding non-radioactive materials on the same 
plate. 
2 ml of urine were hydrolyzed by 24 h incubation at 37 ° with 0.5 ml 
/?-glucuronidase/arylsulfatase. The mixture was worked up and 
chromatographed as described above. 
3.8. Arylesterase activity in mouse and rat skin homogenates 
The skins of 4 mice were freed from fat, blood vessels, and hair, im-
mersed into 30 ml ice-cold barbital buffer solution (0.1 mol/1, pH 
8.6) and cut into pieces. These were homogenized with an Ultra-
Turrax (5 x 20 s) at 0 °C and the resulting homogenate centrifuged at 
100,000 g and 0 °C for 30 min. 
The skin of a male rat (weight of the skin approx. 22 g) was homo-
genized in 58 ml of buffer solution as above. 
After 1,18, and 24 h at room temperature the esterase activity of the 
supernatant was determined according to the method of Pilz [8] as 
follows: 5-6 samples ranging from 0.05 to 1 ml each were diluted to 
1 ml with barbital-EDTA buffer. After addition of 25 ml substrate 
solution (phenyl acetate), they were incubated for 30 min at 37 °C 
in an N 2 atmosphere. 
Between 1 and 24 h at room temperature, the esterase activity of the 
homogenate remained constant, whereas 15 min heating at 80 °C re-
sulted in deactivation. In experiments with dithranol triacetate and 
dithranol diacetate, these were added to the supernatant as a solu-
tion in dimethyl formamide (10 mg/ml) in a ratio of 1 : 100. The in-
cubation was terminated by addition of twice the volume of chloro-
form. After acidification, the mixture was extracted twice more with 
chloroform. In the combined chloroform extracts, dithranol triace-
tate, dithranol diacetate, and dantron were determined densito-
metrically according to Retzow et al. [9]. 
4. Results and discussion 
Due to the two different radioactive labels, we were able to 
determine the excretion pathways of the 3H-labelled anthra-
cene nucleus and the 1 4C-labelled acetoxy substituents sepa-
rately. 
4.1. Elimination kinetics after i.v. and p.o. administration 
Data on the fate of the acetyl substituents of dithranol 
triacetate (2) can be obtained from 14C-measurements in the 
excretion products when compared with data from analo-
gous experiments with authentic [1-14C]acetate. 
After i.v. injection of [14C]-2, an essential part (72% of the 
dose) is recovered as 1 4 C 0 2 in expired air already within 1 
day. Within 3 days, only 8% of the dose are excreted with 
urine and 3% with feces (Table 1), and approx. 9% are still 
left in the organism. 
The experiments with [l-14C]acetate gave similar results (Ta-
ble 2): 83% of the dose appear as 1 4 C 0 2 in expired air, a 
small percentage is present in urine, and 11% are still in the 
organism after 1 day. 
These data indicate that already during the first day after in-
jection the three acetate groups are removed from the mole-
cule almost completely. They obviously enter the acetate 
pool "of the body where they are readily metabolized to 
1 4 C 0 2 . A small portion is incorporated into endogenous sub-
stances, resulting in a longer residence time in the body. 
After oral administration of [14C[-2, rate and mode of excre-
tion are virtually the same as after i.v. injection, the mode of 
administration being reflected only in a somewhat more 
pronounced excretion with feces (Table 3). 
After i.v. injection of the material labelled with 3 H in the an-
thracene ring system, degradation of the label resulted in the 
formation of a substantial amount of 3 H 2 0 (42%). Only 40% 
of the dose are excreted, in equal parts in urine and feces, as 
non-volatile products within 3 days. After this period, 6% of 
the dose are still present in the body as non-volatile material 
and 19%as 3 H 2 0(Table4). 
Table 1: Excretion of 1 4 C after i.v. injection of [14C]dithranol triacetate (2) into 
a rat (in % of radioactive dose). 
Collection period 
(h) 0-24 24-48 48-72 0-72 
1 4 C 0 2 in 
exhaled air 72.1 5.1 1.8 79.0 
1 4 C in urine 6.4 1.0 0.6 8.0 
1 4 C in feces 1.5 0.7 0.8 3.0 
Residual 1 4 C in the orga- \ 
nism after 72 h 8.6 
Total recovery of 1 4 C 80.0 6.8 v 3.2 98.6 
Table 2: Excretion of 1 4 C after i.v. injection of [l-14C]acetate into a rat (in % 
of radioactive dose). 
Collection period 
(h) 0-3 3-24 0-24 
1 4 C 0 2 in 
exhaled air 74.6 8.1 82.7 
1 4 C in urine - 4.1 4.1 1 4 C in feces - 0.8 0.8 Residual 1 4 C in the orga-
nism after 24 h - - 10.9 
Total recovery of 1 4 C 74.6 13.0 98.5 
Table 3: Excretion of 1 4 C after oral administration of [14C]dithranol triacetate 
(2) to a rat (in % of radioactive dose). 
Collection period 
(h) 0-24 24-48 48-72 0-72 
1 4 C 0 2 in 
exhaled air 58.6 4.6 1.2 64.4 
1 4 C in urine 3.6 0.7 0.3 4.6 
1 4 C in feces 10.5 8.9 0.4 19.8 
Residual 1 4 C in the orga-
nism after 72 h 6.1 
Total recovery of 1 4 C 72.7 14.2 1.9 94.9 
Table 4: Excretion of 3 H as non-volatile compounds and 3 H 2 0 after i.v. in-
jection of [3H]dithranol triacetate (2) into a rat (in % of dose; n.v. = non-
volatile labelled material; 3 H 2 0 = tritiated water). 
Collection period 
(h) 0-24 24-48 48-72 0-72 
3 H in n.v. _ 
exhaled air 3 H 2 0 7.9 
3 H in urine n.v. 15.5 1.5 0.8 17.8 
3 H 2 0 3.6 3.6 2.9 10.1 
3 H in feces n.v. 12.2 6.6 3.7 22.5 
3 H 2 0 1.9 1.3 1.6 4.8 
Residual 3 H in n.v. 5.8 
the organism 3 H 2 0 18.9 
Recovery n.v. 27.7 8.1 4.5 46.1 
o f 3 H 3 H 2 0 5.5 4.9 4.5 41.7 
Total recovery of 3H-dose 87.8 
Apparently, [3H]-2 loses, after complete or partial enzymatic 
cleavage of the acetate groups, its 3H-label in an Se-reaction 
with ^ O , i.e. in reverse to the tritiation reaction with 
which it had been obtained originally. 
4.2. Identification of urine metabolites 
Derivatives of anthrone can be metabolized in Phase 1 reac-
tions, i.e. oxidation and hydroxylation. These metabolites, 
in turn, can be further conjugated in Phase 2 reactions with 
sulfuric and glucuronic acid [10]; they are subsequently ex-
creted as such. For identification of dithranol triacetate me-
tabolites, urine samples obtained in the previous balance ex-
periments were both extracted directly and after hydrolysis 
with aryl sulfatase/glucuronidase with methylene chloride 
and investigated by T L C . Thus, only 10% of the total urine 
radioactivity were found to be present as non-conjugated 
metabolites. 
Fig. 1 shows the T L C and the distribution of 3 H -
radioactivity in untreated urine, a small proportion of which 
can be attributed to unchanged 2, dithranol diacetate (3) and 
dantron diacetate (6). 
The by far largest part remains close to the origin, presuma-
bly as polar conjugates. After enzymtic hydrolysis, addition-
al metabolites can be identified: dithranol (1), dantron (5) 
and dithranol monoacetate (4) (see Fig.2). A rather large 
peak occurs at the same Rf as unchanged 2, and an-
other one can be located in the lower third of the chromato-
gram. The latter does not correspond to any of the known 
potential metabolites of 2. It may represent one of the hy-
droxylated species referred to earlier, but could not be iden-
tified c}ue to lack of material. 
4.3. Percutaneous absorption 
To test the absorption through the skin of dithranol triace-
tate, balance studies were performed after dermal applica-
tion of both the 1 4 C - and 3H-labelled forms, analogous to 
those described for i.v. injection. By comparison of these 
data with those obtained for 100% absorption (i.e., i.v. data), 
and considering the differences of metabolic fate of the two 
labels, it should be possible to draw conclusions regarding 
the absorption rate and nature of the absorbed material. 
After dermal application of a preparation of 1 4C-2 in white 
petrolatum with occlusive protection, 1.9% of the radio-
active dose were exhaled as 1 4 C 0 2 within 3 days, and 0.3% 
were excreted in urine. A n additional 2% were found ab-
sorbed in the body. After dermal application of 1 4C-2 in 
dimethyl sulfoxide (DMSO) solution, slightly more ra-
dioactivity was excreted with urine and feces (Table 5). 
A similar experiment with [l-14C]acetate in 50% aqueous 
DMSO was performed to obtain basic information (Table 6). 
From the amount of radioactivity in expired air, urine, 
feces and organism, an absorption rate of approx. 33% for 
Table 5: Excretion of 1 4 C after dermal administration of [14C]dithranol triace-
tate in white petrolatum (A) and in dimethylsulfoxide (B) (in % of radioactive 
dose) to a rat. 
Collection A B 
period (h) 0-24 24-48 48-72 0-72 0-24 24-48 48-72 0-72 
1 4 C 0 2 in 
exhaled air 0.8 0.6 0.5 1.9 1.7 0.4 0.3 2.4 
1 4 C in urine 0.1 0.1 0.1 0.3 0.3 0.1 0.1 0.5 
1 4 C in feces 0.0 0.1 0.1 0.2 0.2 0.2 0.2 0.6 
Residual 1 4 C in the 
organism after 72 h 2.0 0.8 
Table 6: Recovery of 1 4 C after dermal administration of [l-14C]acetate to 2 
rats. Dose: 0.25 mg in 0.1 ml D M S O / H 2 0 1:1 on 4 cm 2 skin (in % of radio-
active dose, mean of two experiments). 
Collection period 
(h) 0-8 8-24 0-24 
1 4 C 0 2 in air 14.1 8.9 23.0 
1 4 C in urine - - 2.3 1 4 C in feces - - 1.1 
1 4 C in skin (area of 
administration) - - 11.2 
Residual 1 4 C in the orga-
nism after 24 h 6.6 
1 4 C in the dressing material 41.9 
Table 7: Excretion of 3 H after dermal administration of [3H]dithranol triace-
tate in dimethylsulfoxide (in % of radioactive dose) to a rat. 
Collection period 
(h) 0-24 24-48 48-72 0-72 
3 H in exhaled air 4.2 
3 H in urine 4.4 2.2 1.6 8.2 
3 H in feces 4.2 1.3 2.9 8.4 
Residual 3 H in the 
organism after 72 h 6.8 
Table 8: Incubation of dithranol triacetate (2) and dithranol diacetate (3) with 
homogenates of rat skin (100,000 g supernatant). TLC-separation of metabo-
lites. 
Substrate 
Metabolite Dithranol triacetate (2) Dithranol diacetate (3) 
I II III I II III 
Dithranol triacetate (2) +++*) +++ +++ 
Dithranol diacetate (3) + + _ + ++ +++ 
Dantron diacetate (6) ++ + _ +++ ++ + 
Dithranol monoacetate (4) - - - ++ + Dantron monoacetate (7) + + _ + + _ 
Dantron (5) ++ + - +++ +++ + 
*) +++ denotes intense, ++ medium, + weak, and - no spot on the thin layer 
chromatogram with the Rf of the metabolite in question. 
I: Homogenate dil. 1:5 with barbital buffer. 
II: Homogenate dil. 1:10 with barbital buffer. 
I l l : Buffer solution only (no homogenate added). 
acetate can be calculated. A comparison between these ex-
periments clearly shows that intact 2 is absorbed to a very l i -
mited extent only. It might even be possible that 2 is enzy-
matically deacetylated, the resulting free acetate being the 
only absorbed species. 
This question could be answered by an experiment with 
3H-2, i.e. with a dithranol triacetate labelled in the anthra-
cene ring system (Table 7). After dermal application in 50% 
aqueous DMSO with occlusive protection a total of 27% of 
the radioactive dose was recovered within 3 days in excre-
tion products (expired air, urine, and feces) and in the car-
cass. This part of the 3H-2 dose then must have been ab-
sorbed through the skin. Considering the results with ace-
tate-labelled 1 4C-2 where only 4.3% had been absorbed, it 
can be concluded that 2 is metabolized in or on the skin 
with formation of free dithranol (or partially acetylated 
derivatives) which in turn is absorbed. 
4.4. Formation of metabolites by skin homogenates 
To test the hypothesis of ester cleavage by enzymes present 
in or on the skin, we subjected 1 4C-2 to the action of skin ho-
mogenates in vitro. Cell-bound, oxidative enzyme systems 
were excluded from the experiments by use of only the 
100,000 g supernatant. 
With phenyl acetate as substrate under our incubation con-
ditions, we found an aryl esterase activity of 6.2-7.8 U/g of 
mouse skin and 4.6-6.0 U/g or 1.14-1.46 x 102 U/mm 2 in 
rat skin. 
With dithranol triacetate (2) as substrate and the 100,000 g 
supernatant of rat skin homogenate, a mixture of a large 
amount of unchanged substrate (2) in addition to dantron 
(5), dantron monoacetate (7), dantron diacetate (6), and di-
thranol diacetate (3) was formed (see Tab1 S). 
Dithranol diacetate as substrate gave thv ime metabolites, 
the difference being the presence of dithranol monoacetate 
(4) and very little unchanged 3 among the metabolites. 
In the enzyme free buffer, dithranol triacetate (2) is stable, 
whereas dithranol diacetate (3) decomposed slowly to give 
some dantron (5). 
Incubation of mice skin homogenates with the two dithranol 
esters gave a similar composition of metabolites. 
These results show the central acetoxy group in the dithra-
nol triacetate molecule to be preferentially hydrolyzed by 
the action of enzymes. The resulting dithranol diacetate is 
quite sensitive to non-enzymatic oxidation reactions, in con-
trast to the original triacetate. 
After administration, the latter is converted to active meta-
bolites only after it has penetrated into the skin thus showing 
a pronounced pro-drug character for the treatment of psoria-
sis. 
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